Other

Unrealized Gain (Loss) on Securities

Year-over-year, this metric declined by 454.6%, from $1.03M to -$3.65M. Over 3 years (FY 2021 to FY 2025), Unrealized Gain (Loss) on Securities shows an upward trend with a -2.8% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID: cop_unrealized_gain_loss_on_securities

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value-$247.00K-$64.00K-$1.67M-$7.22M-$1.73M-$2.05M$4.13M-$2.03M$1.88M$7.04M-$3.57M-$727.00K$9.08M-$4.79M$1.03M-$343.00K$1.13M$0.00-$3.65M
QoQ Change—+74.1%<-999%-333.2%+76.0%-18.4%+300.9%-149.1%+192.7%+274.9%-150.7%+79.6%>999%-152.7%+121.5%-133.3%+429.7%-100.0%—
YoY Change————-602.0%<-999%+157.2%-16.8%+191.5%—-186.5%+64.1%+383.4%-168.0%+128.9%+52.8%-87.5%+100.0%-454.6%
Range-$7.22M – $9.08M
CAGR+82.0%
Avg YoY Growth-253.2%
Median YoY Growth+18.0%
Current Streak2 quarters decline

Frequently Asked Questions

What is Alnylam Pharmaceuticals's unrealized gain (loss) on securities?
Alnylam Pharmaceuticals (ALNY) reported unrealized gain (loss) on securities of -$3.65M in Q1 2026.
How has Alnylam Pharmaceuticals's unrealized gain (loss) on securities changed year-over-year?
Alnylam Pharmaceuticals's unrealized gain (loss) on securities decreased by 454.6% year-over-year, from $1.03M to -$3.65M.
What is the long-term trend for Alnylam Pharmaceuticals's unrealized gain (loss) on securities?
Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's unrealized gain (loss) on securities has grown at a -2.8% compound annual growth rate (CAGR), from -$1.98M to $1.82M.